arginyl-glycyl-aspartic acid has been researched along with eptifibatide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KM; Coller, BS; Weisman, HF | 1 |
| Adderley, SR; Fitzgerald, DJ | 1 |
| Lapalme, G; Tardif, P; Thibault, G | 1 |
| Proimos, G | 1 |
| Aster, RH; Bougie, DW; Rasmussen, M; Zhu, J | 1 |
| Bardania, H; Dorkoosh, F; Faizi, M; Kobarfard, F; Naraki, M; Shojaosadati, SA; Zadeh, ME | 1 |
2 review(s) available for arginyl-glycyl-aspartic acid and eptifibatide
| Article | Year |
|---|---|
The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombosis; Tirofiban; Tyrosine | 1996 |
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Interactions; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Proteins; Receptors, Thrombin; Thrombin; Tirofiban; Tyrosine | 2001 |
4 other study(ies) available for arginyl-glycyl-aspartic acid and eptifibatide
| Article | Year |
|---|---|
Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation.
Topics: Alanine; Animals; Apoptosis; Benzamidines; Caspase 3; Caspases; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium; Enzyme Activation; Enzyme Precursors; Eptifibatide; Humans; Kinetics; Ligands; Mice; Myocardium; Oligopeptides; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rats; Rats, Wistar; Time Factors; Umbilical Veins | 2000 |
Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists.
Topics: Animals; Binding, Competitive; Blood Platelets; Cells, Cultured; Eptifibatide; Fibroblasts; Heart; Humans; Intercellular Signaling Peptides and Proteins; Oligopeptides; Peptides; Peptides, Cyclic; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Sprague-Dawley; Skin | 2001 |
Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.
Topics: Animals; Antibodies; CHO Cells; Cricetinae; Cricetulus; Eptifibatide; Humans; Ligands; Mice; Mice, Inbred BALB C; Models, Biological; Oligopeptides; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Conformation; Rats; Substrate Specificity; Thrombocytopenia; Tirofiban; Tyrosine | 2012 |
Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity.
Topics: Blood Platelets; Cell Death; Cells, Cultured; Drug Carriers; Drug Delivery Systems; Eptifibatide; Humans; Liposomes; Nanoparticles; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors | 2017 |